Identification of Mitochondrial DNA Polymorphism on Linezolid-induced Toxic Optic Neuropathy Patients

Dwi Indira Setyorini, Zen Ahmad, Ella Amalia, Subandrate Subandrate, Yosafat Beltsazar Hutabarat

Abstract


Drug-resistant tuberculosis (DR-TB) is difficult to eradicate due to several factors, including insufficient treatment and medication side effects. Linezolid is among the medications with serious adverse effects. Linezolid toxicity is suspected to be related to the drug's binding to mitochondrial 16s rRNA. Some studies indicate that polymorphisms in patients' mtDNA may increase vulnerability to the development of toxic optic neuropathy. This study aims to identify a genetic influence on the vulnerability to the occurrence of toxic optic neuropathy side effects in drug-resistant tuberculosis patients receiving linezolid treatment. This research was conducted at the Faculty of Medicine, Universitas Sriwijaya, Palembang, from September to October 2023. Polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) was undertaken to detect mutations in the G3010A mtDNA of the patients. Two patients experiencing toxic optic neuropathy side effects during drug-resistant tuberculosis treatment underwent blood sample collection. Blood samples were examined for mutations in the G3010A and A2706G genes using the PCR-RFLP method. The PCR-RFLP examination results indicated the presence of mutations in G3010A. In conclusion, polymorphism of G3010A mtDNA may contribute to the vulnerability to toxic optic neuropathy side effects in drug-resistant tuberculosis patients receiving linezolid. Further research with a larger population is needed to prove the involvement of mtDNA polymorphisms in the vulnerability to toxic optic neuropathy.

Keywords


DR-TB; linezolid, MtDNA: toxic optic neuropathy

Full Text:

PDF

References


World Health Organization. Global tuberculosis report 2023. Geneva: World Health Organization; 2023.

Kementerian Kesehatan Republik Indonesia. Dashboard data kondisi TBC di Indonesia [Internet]. 2023 [cited 2023 Sep 19]. Available from: https://tbindonesia.or.id/pustaka-tbc/dashboard/.

Bolhuis MS, Tiberi S, Sotgiu G, De Lorenzo S, Kosterink JG, van der Werf TS, et al. Linezolid tolerability in multidrug-resistant tuberculosis: a retrospective study. Eur Respir J. 2015;46(4):1205–7.

Dempsey SP, Sickman A, Slagle WS. Case report: linezolid optic neuropathy and proposed evidenced-based screening recommendation. Optom Vis Sci. 2018;95(5):468–74.

Lifan Z, Sainan B, Feng S, Siyan Z, Xiaoqing L. Linezolid for the treatment of extensively drug-resistant tuberculosis: a systematic review and meta-analysis. Int J Tuberc Lung Dis. 2019;23(12):1293–307.

Spinazzi M. Optic neuropathies caused by micronutrient deficiencies and toxins. In: Preedy VR, editor. Handbook of nutrition, diet and the eye. Oxford: Elsevier; 2014. p. 383–92.

Sharma P, Sharma R. Toxic optic neuropathy. Indian J Ophthalmol. 2011;59(2):137–41.

Ishii N, Kinouchi R, Inoue M, Yoshida A. Linezolid-induced optic neuropathy with a rare pathological change in the inner retina. Int Ophthalmol. 2016;36(6):761–6.

Direktorat Jenderal Pencegahan dan Pengendalian Penyakit, Kementerian Kesehatan Republik Indonesia. Petunjuk teknis penatalaksanaan tuberkulosis resistan obat di Indonesia. Jakarta: Kementerian Kesehatan Republik Indonesia; 2020.

Wasserman S, Meintjes G, Maartens G. Linezolid in the treatment of drug-resistant tuberculosis: the challenge of its narrow therapeutic index. Expert Rev Anti Infect Ther. 2016;14(10):901–15.

Conradie F, Diacon AH, Ngubane N, Howell P, Everitt D, Crook AM, et al. Treatment of highly drug-resistant pulmonary tuberculosis. N Engl J Med. 2020;382(10):893–902.

Santini A, Ronchi D, Garbellini M, Piga D, Protti A. Linezolid-induced lactic acidosis: the thin line between bacterial and mitochondrial ribosomes. Expert Opin Drug Saf. 2017;16(7):833–43.

Mehta S, Das M, Laxmeshwar C, Jonckheere S, Thi SS, Isaakidis P. Linezolid-associated optic neuropathy in drug-resistant tuberculosis patients in Mumbai, India. PLoS One. 2016;11(9):e0162138.

Brandariz-Núñez D, Hernández-Corredoira V, Guarc-Prades E, García-Navarro B. Optic neuropathy associated with linezolid: systematic review of cases. Farm Hosp. 2019;43(2):61–5.

Bano S, Nawaz A, Numan A, Hassan MA, Shafique MBA. A case report and literature review of the outcome of linezolid-induced optic and peripheral neuropathy in patients with multidrug-resistant pulmonary TB. Front Neurol. 2022;13:908584.

Toolan KJ, Fondriest J, Keenan K, Mizen T, Stosic M. Linezolid toxic optic neuropathy: a case report and review of visual prognosis. Am J Ophthalmol Case Rep. 2023;32:101922.

Shree R, Mahesh KV, Takkar A, Modi M, Goyal MK, Lal V. The neuro-ophthalmology of tuberculosis. Neuroophthalmology. 2023;48(2):73–92.

Song T, Lee M, Jeon HS, Park Y, Dodd LE, Dartois V, et al. Linezolid trough concentrations correlate with mitochondrial toxicity-related adverse events in the treatment of chronic extensively drug-resistant tuberculosis. EBioMedicine. 2015;2(11):1627–33.

Lin SY, Stacey AW, Al-Zubidi N, Ponce CP, Bhat N, Bhatti MT, et al. Toxic optic neuropathy [Internet]. San Fransisco: American Academy of Ophthalmology; 2023 [cited 2024 Aug 15]. Available from: https://eyewiki.org/Toxic_Optic_Neuropathy.

Zhang P, Li W, Liu M, Zhan S, Zhang H, Deng G, et al. Linezolid-associated neuropathy in patients with MDR/XDR tuberculosis in Shenzhen, China. Infect Drug Resist. 2022;15:2617–24.

De Vriese AS, Coster RV, Smet J, Seneca S, Lovering A, Van Haute LL, et al. Linezolid-induced inhibition of mitochondrial protein synthesis. Clin Infect Dis. 2006;42(8):1111–7.

Vallabhaneni S, Mendonca TM, Nayak RR, Kamath G, Kamath A. Linezolid induced toxic optic neuropathy in drug resistant tuberculosis-a case series. Indian J Tuberc. 2024;71(Suppl 1):S5–9.

Palenzuela L, Hahn NM, Nelson RP Jr, Arno JN, Schobert C, Bethel R, et al. Does linezolid cause lactic acidosis by inhibiting mitochondrial protein synthesis? Clin Infect Dis. 2005;40(12):e113–6.

Kardani S, Hadia R, Shah A, Parmar G, Maheshwari R, Seth A, et al. A case report on reversible toxic optic neuropathy on long term treatment of linezolid in extensively drug-resistant tuberculosis patient. J Pharm Res Int. 2021;33(37A):7–11.

Srivastava A, Kshetrimayum S, Gupta SK, Kant S. Linezolid-induced optic neuropathy in XDR pulmonary TB: a case series. Indian J Tuberc. 2017;64(2):129–33.

Lee S, Kang BH, Ryu WY, Um SJ, Roh MS, Son C. Is severe and long-lasting linezolid-induced optic neuropathy reversible? Intern Med. 2018;57(24):3611–3.




DOI: https://doi.org/10.29313/gmhc.v13i1.14142

pISSN 2301-9123 | eISSN 2460-5441


Visitor since 19 October 2016: 


Free counters!


Global Medical and Health Communication is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.